Navigation Links
CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Date:10/18/2007

VIENNA, Va., Oct. 18 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) announced today that its Chief Executive Officer, Geert Kersten, is a featured presenter at the International Society for Pharmaceutical Engineering (ISPE) 2007 Chesapeake BioShowcase in Gaithersburg Maryland. Mr. Kersten will present on the "New Realities for Funding a Small Biotechnology Company" today at 3:15 p.m. (Eastern Daylight Time).

In April 2007, CEL-SCI completed a $15 million private placement of common stock and warrants at a premium to where its common stock was trading at the time. In addition, in August 2007, CEL-SCI entered into a novel $15 million financing transaction in which it acquired the 20 year use of a dedicated manufacturing facility for its Phase III cancer drug Multikine(R). CEL-SCI is in the strongest financial condition in the Company's history.

ISPE is the Society of choice for 25,000 pharmaceutical manufacturing professionals in 90 countries around the globe. ISPE aims to be the catalyst for "Engineering Pharmaceutical Innovation" by providing Members with opportunities to develop technical knowledge, exchange practical experience, and collaborate with global regulatory agencies and industry leaders.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... 2020 , ... Bleep LLC, maker of the DreamPort mask-less CPAP solution, announced ... new spokesperson. , “In my line of work, a good night of sleep is ... it was a Bleeping no brainer for me,” said Jensen. “From the moment I ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation ... is an adult and pediatric neuro-oncologist who serves on the Board of Directors at ... at Duke University Medical School. , Internationally recognized, Dr. Friedman is a widely published ...
(Date:8/26/2020)... ... August 26, 2020 , ... ScripHessco ... Sports Injuries. The infographic breaks down ways that chiropractors can help heal sports ... According to ScripHessco “Athletes have an unusual amount of pressure and stress on ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma Research Foundation ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Blood Cancer Awareness Month (BCAM) and its international Light it Red for ...
(Date:8/31/2020)... ... 31, 2020 , ... Want to get moving, break up your routine, and ... is thrilled to launch its fourth annual STEPtember campaign in the United States to ... everyone wherever they are at this moment — encouraging people to move in the ...
(Date:8/31/2020)... ... August 31, 2020 , ... Smile Brands ... groups in the United States, today announced the grand opening of another affiliated ... , Patients will enjoy convenient hours, a comfortable office, and full-service care at ...
(Date:8/31/2020)... ... ... In an effort to give back to the community in which it serves, ... booked with a special new rate code to benefit children and families at ... Donations will be applied to any room type, any time, now through the end ...
(Date:8/29/2020)... ... ... When professor and author Randy Pausch was diagnosed with pancreatic cancer, he accepted ... melancholic, however, he put together a final lecture in Carnegie Hall in which he ... situation and turned it into something that inspired millions of people worldwide. This inclination ...
Breaking Medicine News(10 mins):